Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
PR Newswire•29/10/2026•06:30 ET
0
Key Highlights
- ➤Immunic (IMUX) schedules virtual progressive MS R&D Day for November 5, 2026
- ➤Phase 3 progressive MS trial initiation planned for later in 2026
- ➤Vidofludimus calcium’s potential progressive MS expansion centers on Nurr1 activation
- ➤Relapsing MS Phase 3 top-line data expected by end of 2026
Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026 PR Newswire
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual Research and Development (R&D) Day focused on progressive multiple sclerosis (MS) on Thursday, November 5, 2026, at 12:30 pm ET.
Get started
Create a free account to read the full story.